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Background: When repetitive transcranial magnetic stimulation (rTMS) is used to treat medication re-
fractory depression, the treatment pulse intensity is individualized according to motor threshold (MT).
This measure is often acquired only on the first day of treatment, as per the protocol currently approved
by Food and Drug Administration.
Objective: Here, we aimed to assess daily MT variability across an rTMS treatment course and simulate
the effects of different schedules of MT assessment on treatment intensity.
Methods: We conducted a naturalistic retrospective study with 374 patients from a therapeutic rTMS
program for depression that measures MT daily.
Results: For each patient, in almost half the TMS sessions, MT varied on average more than 5% as
compared to the baseline MT acquired in the first treatment day. Such variability was only minimally
impacted by having different TMS technicians acquiring MT in different days. In a smaller cohort of
healthy individuals, we confirmed that the motor hotspot localization method, a critical step for accurate
MT assessment, was stable in different days, arguing that daily MT variability reflects physiological
variability, rather than an artifact of measurement error. Finally, in simulations of the effect of one-time
MT measurement, we found that half of sessions would have been 5% or more above or below target
intensity, with almost 5% of sessions 25% above target intensity. The simulated effects of weekly MT
measurements were significantly improved.
Conclusions: In conclusion, MT varies significantly across days, not fully dependent on methods of MT
acquisition. This finding may have important implications for therapeutic rTMS practice regarding safety
and suggests that regular MT assessments, daily or at least weekly, would ameliorate the effect.
© 2021 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Noninvasive Brain Stimula-
t of Neurology, Beth Israel
, Boston, 330 Brookline Ave
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Major depressive disorder (MDD) is a common psychiatric dis-
order, affecting more than 300 million people worldwide, and ac-
counting for 10% of all years lived with disability globally [1].
Importantly, a significant proportion of patients do not respond to
pharmacological treatments [2e4]. Repetitive transcranial mag-
netic stimulation (rTMS) of the dorsolateral prefrontal cortexC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(TRD) [5], with evidence for long-lasting efficacy among patients
that respond to this treatment [6]. For those who do not respond to
rTMS, patient-related factors [7], as well as treatment-related fac-
tors such as the location of stimulus application [8,9], may account
for reduced neuromodulatory and clinical effects [10,11]. Treatment
dose, which is individualized according to resting motor threshold
(MT), could also influence antidepressant response [12,13].
Motor threshold is the intensity of motor cortex stimulation that
produces at least 50% successful motor responses in the contra-
lateral hand in a series of consecutive stimuli [14]. In currently
approved protocols, including by Food and Drug Administration
(FDA), for therapeutic rTMS in TRD [12,15], stimulation dose is
individualized for each patient according to the MT measured on
the first day of treatment, and then kept constant across days.
However, it is unclear if variability of MT across days is significant,
and if this contributes toward treatment efficacy and/or safety. In
fact, MT varies according to different factors such as changes in
sleep [16], diet [17], time-of-day [18], and medical conditions [19],
among others [20]. If MT does in fact vary across a course of TMS for
depression treatment, protocols with infrequent MT determination
could provide ineffective stimulation due to “underdosing” in ses-
sions where MT has increased, or raise safety concerns due to
“overdosing” in sessions where MT has decreased [21].
Here, using retrospective data from a TMS clinical center where
MT is acquired and recorded daily, we describe daily MT variability
across treatment courses. Using these data, we also simulate the
potential for over or understimulation in each therapeutic session if
MT is measured at a less-than-daily frequency. In a separate smaller
group of healthy individuals, we further test the stability of
methods for MT acquisition, namely regarding motor hotspot (M1)




We conducted a naturalistic retrospective study, with data from
patients treated at the Berenson-Allen Center for Noninvasive Brain
Stimulation (BA-CNBS) from 2000 to 2019, in compliance with local
Internal Review Board approval for publication of clinical data.
2.2. Population
Adult patients treated with DLPFC rTMS for depression, using
either Magstim or Neuronetics devices, were eligible. Depression
was considered as any major depressive episode in the context of
either MDD or bipolar disorder type II, according to the Diagnostic
and Statistical Manual of Mental Disorders [22e24]. Patients were
excluded if MT for the first rTMS session could not be retrieved
(n ¼ 16), if treatment device was changed during the treatment
course (n ¼ 5), if less that 10 rTMS sessions were conducted in total
(n ¼ 9), or if average interval between consecutive sessions was 2.5
days or more (N ¼ 8). Furthermore, for analyses where treatment
response or remission was considered, patients with baseline Beck
Depression Inventory-II (BDI-II) [25] score less than 14 [26], were
also excluded (N ¼ 24).
2.3. Variables
Age, gender, baseline and follow-up severity scores (BDI-II and
17 item-Hamilton Depression Rating Scale e HAM-D-17) [27], daily
stimulation parameters (device, coil, stimulation-side, stimulation
intensity, frequency, total number of pulses per session),1119medication and MT were extracted from the electronic clinical
database, whenever available. There was also variability in TMS
technician, and therefore, this factor was extracted whenever
available.
MT was determined from the motor hotspot (M1) using the
visual method in accordance with the available clinical recom-
mendations [28]. In the application of these methods, trained TMS
technicians started by locating the cranial vertex at the cross-
section between the nasion-inion mid-sagittal line and the inter-
tragus line. The center of the stimulating coil was then placed on
a point 5 cm from the vertex on the inter-tragus line, which was the
starting point for functional location of M1. With the TMS output
set to a low intensity, stimulation pulses were delivered, and the
contralateral hand inspected visually for muscle twitching, with
intensity increased after at least 3 stimuli without a response. Once
a visible twitch was observed in the target muscle-group, i.e.,
abductor pollicis brevis or first digit interosseous, intensity was kept
constant to compare muscle twitching responses obtained from
stimuli applied to other locations, namely 0.5 cm and 1 cm anterior,
posterior, medial and lateral to the original stimulation point. The
location eliciting, most consistently, the largest muscle twitch of
the targetmuscles was thus defined as theM1. The treatment target
in the dorsolateral prefrontal cortex (DLPFC) was then identified as
the point 5e5.5 cm anteriorly to M1, on the corresponding para-
sagittal line, according to the available clinical recommendations
[28].
Once M1 location was defined, the resting MT for M1 was
determined according to the visual method, one of the strategies
supported in the consensus recommendations for clinical applica-
tion of rTMS in depression treatment [28], systematized according
to our center experience and best clinical practice. In this process,
starting with the supra-threshold stimulation intensity used to
locate M1, 10 pulses, spaced 6e10 s apart were delivered at M1
while visually inspecting the target muscle for muscle twitching.
Intensity was then reduced by 2% in sequential steps, until less than
5 out of 10 TMS trials elicited a visible muscle twitch (i.e., below
threshold). Finally, intensity was increased by 1% and, if at least 5 of
10 TMS trials elicited a visible muscle twitch, that intensity was
defined as the motor threshold. Biphasic pulse shape was used in
MT determination and during the treatment sessions.
2.4. Data analysis
All data were analyzed using StataCorp. 2017. Stata Statistical
Software: Release 15. College Station, TX: StataCorp LLC. Clinical
response to rTMS was calculated as the percent reduction of BDI-II
depression severity scores at the last measurement, relative to
baseline (BDI-response). Normalized MT (nMT) was calculated in
each patient for all treatment days after the first (day2-30), as the
ratio of that day MT relative to MT on the first day (nMT2-30 ¼MT2-
30/MT1). In a simulation analysis, the actual treatment stimulation
intensity for the first day (aSI1) was 120% MT and considered as the
treatment stimulation intensity that would have been used in the
following days if MT had been measured only on the first day. The
simulated stimulation intensity (sSI) for the following days, sSI was
calculated according to a ratio of aSI1 and the MT measured on the
following days: [sSIX¼(aSI1/MTX)*100]% of MT. Similar computa-
tions were performed to simulate sSI if MT had been measured
weekly ([w1sSIX to w6sSIX]% of MT), using aSI1, aSI6, aSI11, aSI16, aSI21
and aSI26 for weeks 1, 2, 3, 4, 5 and 6, respectively. Please see Fig. S1
for further details on data analysis calculations. The percentage of
sessions per patient in determined nMT intervals (<0.75, [0.75;
0.85[, [0.85; 0.95[, [0.95; 1.05[, [1.05; 1.15[, [1.15; 1.25[ and1.25) as
well as sSI intervals (<95%, [95; 105%[, [105; 115%[, [115; 125%[,
[125; 135%[, [135; 145%[ and 145%) was then calculated, as was
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(1e3, 4e6, 7e9 and 10) in each of the sSI intervals.
Data for continuous measurements (age, number of sessions,
MT, BDI-II, HAM-D-17, BDI-response, HAM-response, nMT, sSI,
percent sessions in determined nMT or sSI intervals) are presented
as mean ± standard error of the mean (SEM) and analyzed, as
appropriate, using unpaired two sample t-tests, analysis of variance
(ANOVA) and longitudinal mixed effects regression analyses. Binary
outcomes (gender, stimulation side and patients with a given
number of sessions within each of the sSI intervals) are presented
as percentage of patients (%) and analyzed using Chi-square tests. In
a sub-cohort of individuals (N ¼ 89) for whom information of
identity of TMS technician in each day was available, we calculated,
for each patient, mean consecutive nMT variability, separately for
consecutive rTMS sessions performed by the same and by a
different TMS technician, and are also presented as mean ± SEM.
Paired t-tests were used to compare nMT variability across patients
between same vs. different TMS technician.
2.5. Reliability of M1 localization
In addition to the retrospective study described above, a small
cohort of healthy individuals were also recruited prospectively, at
the Champalimaud Center for the Unknown (CCU), to assess test-
retest reliability of M1 localization procedures and determine
whether this could contribute to MT variability. The protocol con-
sisted in determination of left M1 location in two separate days and
was performed according to protocol approved by the local ethics
committee, in accordance with the Declaration of Helsinki. Ten
right-handed healthy adults, ages 22-50 years-old, five of whom
male, were recruited. Previously acquired T1-weighted MRI brain
scans from each participant were loaded into a Visor 2 Neuro-
navigation System (ANT Neuro, Enschede, Netherlands) for
neuronavigation-based measurements. In each session a trained
TMS technician located M1 according to the methodology
described above and saved stereotaxic coordinates for later offline
analysis. The TMS technician was the same for all research subjects
in both sessions and was blinded to neuronavigation images and
coordinates. The anatomical images and associated target co-
ordinates from the neuronavigation systemwere co-registered into
a common anatomical space (MNI152; http://nist.mni.mcgill.ca/)
using a composition of 3D-rigid and affine transformations in 3D-
Slicer Software. The procedure was repeated in two sessions in
order to assess between-session reliability. Scalp and cortical co-
ordinates for left M1, as well as the within-subject distance be-
tween the same target measured in different sessions, were
acquired offline using Visor 2 tools. To assess between-session
reliability of left M1 localization we first computed the absolute
scalp distance between left M1 “hotspots” in the two sessions and
calculated the respective coefficient of variation (CV¼SD/
Mean*100). Furthermore, we computed the intraclass coefficient
(ICC), absolute agreement, using a two-way mixed-effects model
[29] between the two sessions. We extracted the distance of each
M1 coordinate to the origin of the coordinates system (0, 0, 0), and
compared the two distances for each participant. We also
computed CVs for such distances in each session (CV1; CV2).
3. Results
Clinical and demographic characteristics of the retrospective
sample of depressed patients treated with rTMS are presented in
Table 1, with comparisons of baseline characteristics for patients
treated with each of the two main devices used in this treatment
center. In patients where medication was systematically reported
(N ¼ 175), we found that 96.0% were on any type of medication:1120Benzodiazepines e 50.9%; Antipsychotics e 43.4%; Anticonvulsants
e 34.3%; Selective Serotonin Reuptake Inhibitors e 34.3%; Seroto-
nin and Norepinephrine Reuptake Inhibitors e 32.0%; Bupropion e
14.9%; Lithium e 14.3%. Raw MT values were not directly compa-
rable across devices due to different scales. However, nMT could be
calculated and compared for the two devices. We found that nMT
did not change across the course of therapy (2.5*104±1.5*104,
p ¼ 0.1; Fig. 1A) and that there was no significant effect of gender,
age, side of stimulation, year of treatment or baseline BDI on nMT
(2.0*104±1.7*104, p ¼ 0.2). No differences in nMT variability
across time were found according to responder status (responder
vs. non-responder; Fig. 1B) or stimulation device (Magstim vs.
Neuronetics; Fig. S2). On analyses of per-patient summary data
across treatment days, MT varied 5% or more above or below the
first MT, on average, in almost half of the sessions per patient
(42.0 ± 0.4%), with more extreme variations (25% above or below
the first MT) in, on average, 1.3 ± 0.2% of sessions per patient
(Fig. 1C). Also, on the per-patient analyses, while the aforemen-
tioned variations were similar among the two stimulation devices
(Fig. S3) and between early (2000e2007) and later (2008e2019)
years of treatment (Fig. S4), there were differences between re-
sponders and non-responders, suggesting a greater tendency for
MT reduction across sessions in responders (Fig. 1D). These ana-
lyses were repeated using raw MT values, separately for Magstim
and Neuronetics and, while the differences between responders
and non-responders were not reproduced, possibly due to reduced
statistical power, nMT variability across timewas consistent in both
sub-cohorts.
To explore factors that could influence day-to-day variability in
MT measurements, in patients for whom such data was available,
we compared mean nMT variability in consecutive treatment days,
according to presence vs. absence of variation in TMS technician.
For patients for whom TMS technician was systematically recorded
on a daily basis (N ¼ 89), per patient mean consecutive day nMT
variability was, on average, slightly higher when the technician
changed, compared towhen it was performed by the same operator
(3.6 ± 0.2% vs. 2.9 ± 0.2% respectively; p ¼ 0.0001, paired t-test).
Furthermore, when comparing the performance of individual
technicians regarding mean nMT variability in consecutive days
across patients i.e., the session-to-session variability for a specific
technician, the amount of variability in MT did not differ among
technicians, with mean nMT variability across technicians of
3.1 ± 0.2% (p ¼ 0.1, linear regression).
Given the evidence that daily variability inMTwas only partially
explained by variation in the TMS technician, and also the evidence
for equivalent performance between TMS technicians regarding
consecutive nMT variability, a major source of MT variability could
be due to motor hotspot location variability. In a separate pro-
spective cohort (Table 2), we assessed between day stability in M1
localization, a potential source of MT daily variability. This was
donewith a single rater i.e., TMS technician, using the samemethod
as that described for the retrospective patient cohort, across TMS
sessions, in two separate days. Noteworthy, the single rater had
similar left-side nMT variability (3.0 ± 0.8%) relative to the afore-
mentioned technicians, when assessing MT in similar circum-
stances. When comparing M1 location identified in each of the two
experimental sessions using a neuronavigation system (please see
methods for details), we found that median scalp distance between
targets was 8.2 mm (IQR ¼ 5.8e8.9; CV ¼ 44.8%), while the intra-
class coefficient correlation (ICC) for cortical distances of each M1
location to the origin of the coordinate system (0, 0, 0) was high
(ICC Average ¼ 0.8, 95% CI 0.4e1.0; ICC Individual ¼ 0.7, 95% CI 0.3e0.9;
F [9,9] ¼ 6.4; p ¼ 0.006) and the respective CVs for each session
extremely low (CV1 ¼ 3.9%; CV2 ¼ 5.2%), confirming that M1 was
consistently found within less that 1 cm of the previous location.
Table 1
Clinical and demographic characteristics of the study sample.
Characteristic Total Sample (N ¼ 374) Magstima vs. Neuroneticsb
Magstim (N ¼ 282) Neuronetics (N ¼ 92) P value
Mean ± SEM or % Mean ± SEM or % Mean ± SEM or %
Age 50.0 ± 0.8 49.1 ± 1.0 52.6 ± 1.5 n.s.
Gender (% Female) 59.0 58.8 59.8 n.s.
Stimulation Side (% Left) 89.4 91.4 83.3 0.03
Nº of sessions 24.3 ± 0.3 24.1 ± 0.4 24.8 ± 0.6 n.s.
Stimulation Intensity (% of MT) 114.6 ± 0.3 112.5 ± 0.4 118.6 ± 0.4 <0.001
Frequency (Hz) 13.5 ± 0.4 13.8 ± 0.4 13.0 ± 0.7 n.s.
Total Number of Pulses 2218.2 ± 40.4 2208.3 ± 47.8 2242.4 ± 76.1 n.s.
Baseline MT N.A. 64.1 ± 0.7 1.1 ± 0.02 N.A.
Mean MT N.A. 63.4 ± 0.7 1.1 ± 0.02 N.A.
Mean nMT 1.0 ± 0.003 1.0 ± 0.004 1.0 ± 0.007 n.s.
Baseline BDI 31.9 ± 0.6 32.1 ± 0.6 31.4 ± 1.2 n.s.
BDI Response (% improvement) 38.4 ± 1.8 38.2 ± 2.0 39.2 ± 3.7 n.s.
BDI Treatment Responsec 42.0% 41.1% 44.7% n.s.
BDI Treatment Remissiond 32.0% 31.3% 34.1% n.s.
Baseline HAMD 22.1 ± 0.4 22.1 ± 0.4 22.0 ± 0.7 n.s.
HAMD Response (% improvement) 39.8 ± 2.1 37.7 ± 2.4 46.1 ± 4.2 n.s.
BDIe Beck Depression Inventory; HAMDeHamilton Depression Rating Scale; MTeMotor Threshold; Ne number of subjects; NºeNumber; N.A.eNon-Applicable; n.s.e not
significant; nMT e Normalized Motor Threshold; SEM e Standard Error of the Mean.
a Magstim D70 Air Cooled coil was used in 279 patients and Brainsway H1 coil was used in 3 patients.
b Neuronetics Precision Pulse TMS coil was used in all patients.
c Response criteria were defined as a reduction of at least 50% from baseline.
d Remission criteria were defined as a final BDI score of 11.
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returned to the data from the retrospective sample of depressed
patients described above and simulated the effects on stimulation
intensity of measuring MT only once at the beginning of the
treatment or once every week. For that, we calculated stimulation
intensity relative to baseline MT, modeling the effects of measuring
MT only once per course of therapy, once weekly, or daily MT
measures, with the simulated stimulation intensity (sSI) relative to
the actual measured MT for that day (see methods for details). In
fact, if MT had been measured only once per course of therapy, as is
in most protocols cleared by the FDA, our simulation shows that, on
average, half of the treatment sessions per patient would have been
performed 5% or more above or below the recommended stimu-
lation intensity (120% MT, i.e., 115e125% MT) [28]. However, the
simulation shows significant advantages for measuring MT weekly
with, on average, only one-third of sessions performed outside of
the recommended intensity window in each patient and, specif-
ically, a lower proportion of sessions being performed at high in-
tensities (Fig. 2; see also Figs. S5AeD). Importantly, when datawere
considered according to number of sessions per patient, rather than
proportion, we found that the majority of patients would have been
treated in the recommended interval (115e125%) for 10 or more
sessions both if MTwas determined once or weekly (61% and 86% of
patients, respectively). On the other hand, 9% and 4% of patients,
respectively, would have been treated with a very high stimulation
intensity (145% MT) in at least 1 session (see Table S1 for further
details).
4. Discussion
To our knowledge, this is the first study reporting daily MT
variability across rTMS depression treatments, allowing for an es-
timate of the effects of different intervals of MT measurement.
Although, on average, MT decreased slightly (but not significantly)
across days, it was 5% or more above or below the first MT, on
average in almost half of the sessions per patient. Thus, while our
results are consistent with prior findings of only minor MT change
across days at a group level [30,31], they demonstrate significant
day-to-dayMT variability, with potential clinical relevance in terms1121of both efficacy and safety, that should be explored in future
studies, designed to evaluate the impact of different MTassessment
schedules. Unfortunately, few studies have assessed the relation-
ship between MT and side effects, or efficacy, and the results have
been inconclusive [31e36].
Different methods of MT estimation, such as RossinieRothwell,
parameter estimation by sequential testing (PEST) or Bayesian
inference PEST variant, have been described as potentially
improving MT intra- and inter-session reliability, while decreasing
the application time [37,38]. Nevertheless, such methods have been
mostly used in research setting, using electromyography (EMG)
rather than visual estimation, which was the method used in our
study. In the clinical context, the visual method is advocated and
widely practiced for ease of use and cost-effectiveness [28].
Because our study aims to inform current clinical practice, EMG-
based methods were not considered, and MT variability could be
potentially impacted by TMS operators. However, while MT vari-
ability may be explained to a small extent by between-technician
differences or variability in M1 localization between sessions, our
data suggest other physiological factors are major contributors to
such variability. In fact, the variability in MTwas only slightly larger
when the technician varied across consecutive days, even if this
small effect (0.7 ± 0.2%) was significant with this large database.
Furthermore, clinical standard M1 localization method was found
to be highly reproducible [39]. Hence, MT variability is unlikely to
be completely dependent on methodologic constraints and could
be reduced but not eliminated if recommended TMS-related pro-
cedures, including TMS technician training, are followed. To this
end, the training recommendations endorsed by the International
Federation of Clinical Neurophysiology provide valuable guidelines
[40]. Individual neurophysiologic changes across treatment days
likely contribute significantly to the observed MT variability. While
such variability could result from somewhat unpredictable factors
such as sleep [16], diet [17] or other factors [20], there are also
suggestions of some degree of predictably related to improvement
from depression [34]. In fact, we found that rTMS responders had
more sessions with MT lower than on the first day, suggestive of
increasing cortical excitability, when compared to non-responders.
This finding is in support of the theory that patients diagnosed with
Fig. 1. Normalized Motor Threshold.
(A) When analyzed using longitudinal regression, daily normalized motor threshold (nMT) was found to decrease slightly, and close to significance, across days in the entire sample
(ß ¼ 2.5*104±1.5*104, p ¼ 0.1). This effect was not significant (ß ¼ 2.0*104±1.7*104, p ¼ 0.2) when adjusting for other variables (gender, age, side of stimulation, year of
treatment and baseline BDI, that were not significantly related to nMT e data not shown) in a longitudinal mixed effects regression model. In this plot, N is the number of patients
with MT available for a specific session; while N mostly drops across time due to attrition, there are increases in some instances due to reductions in missing values. (B) In a
longitudinal mixed effects regression model considering a possible association between nMT and treatment response status, while the decrease of nMT across days was close to
significance (ß ¼ 2.4*104±1.6*104, p ¼ 0.1) there was no effect in the comparison between responders and non-responders (ß ¼ 8.1*103±6.7*103, p ¼ 0.2). These findings
did not change significantly in other models, when adjusting for other variables (gender, age, side of stimulation, year of treatment and baseline BDI); however, while findings did
not change significantly when including an interaction term for response status and days across the whole treatment, we found an interaction between these two variables in the
second third of treatment course, i.e. from 11th e 20th sessions, revealing a tendency for responders to have a greater decrease than non-responders across this period
(ß ¼ 1.5*103±7.5*104, p ¼ 0.04); regardless, post-hoc t-tests did not reveal differences in specific sessions. (C) The percentage of sessions per patient within defined nMT
intervals (<0.75, [0.75; 0.85[, [0.85; 0.95[, [0.95; 1.05[, [1.05; 1.15[, [1.15; 1.25[ and 1.25) varies significantly across such intervals (F(6, 2238) ¼ 471.2, p < 0.00001; repeated measures
one-way ANOVA). (D) In analyses according to treatment response, while differences between nMT intervals were conserved (F(6, 2088) ¼ 422.7, p < 0.00001), treatment response did
not impact nMT (F(1, 348) ¼ 0.03, p ¼ 0.9) but interaction between the two factors was significant (F(6, 2088) ¼ 3.0, p < 0.01; repeated-measures two-way ANOVA). **p < 0.01,
****p < 0.0001, post-hoc Bonferroni corrected t-tests.
Table 2
Characteristics of subjects recruited for motor hotspot intra-rater reliability sessions.
Subject Gender Age (y) Dominant Hand Intersession Distance in Left M1 (mm)
1 Male 26 Right 6.81
2 Female 28 Right 5.58
3 Female 22 Right 7.79
4 Male 40 Right 4.67
5 Male 32 Right 8.60
6 Male 24 Right 5.76
7 Female 26 Right 10.47
8 Male 50 Right 8.54
9 Female 28 Right 18.16
10 Female 36 Right 8.90
M1 e Motor Hotspot; mm e millimeters; y e years.
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Fig. 2. Simulated Stimulation Intensity.
Simulated stimulation intensity (sSI) if MT had been measured only on the first session of treatment, or once at the start of each week, was calculated as defined in the methods
section. As expected the percentage of sessions per patient within defined sSI intervals (<95%, [95; 105%[, [105; 115%[, [115; 125%[, [125; 135%[, [135; 145%[ and 145%) was
significantly different between sSI intervals (F(6, 4476) ¼ 1426.4, p < 0.00001). Furthermore, there was on one hand a significant difference according to frequency of MT mea-
surement (F(1, 746) ¼ 6.8, p ¼ 0.01), but also the two factors interacted significantly (F(6, 4476) ¼ 55.1, p < 0.00001; two-way ANOVA), revealing a clear advantage for weekly relative to
single MT measurement. **p < 0.01, ****p < 0.0001, post-hoc Bonferroni corrected t-tests.
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after successful antidepressant treatment [41]. Nevertheless, future
studies assessing MT should be designed to systematically explore
such hypothesis. Interestingly, the sustained effect of TMS in
cortical excitability might be occurring at the synaptic level, where
increasing synaptic noise has been hypothesized to impact neurons
excitability and plasticity [42].
Our results are of particular relevance, and provide guidance,
regarding the frequency of MT assessment across rTMS treatment
of depression. According to our findings, it is reasonable to expect
that, when MT is assessed only once in the beginning of treatment,
9% of patients will have at least one TMS session performed at very
high intensity (145% MT), potentially posing important safety
concerns. Weekly MT measurement is clearly advantageous when
compared to a single MT measurement, leading to a reduction of
the risk of overstimulation, since only 4% of patients would have
been exposed to significant overstimulation in one session. Addi-
tionally, with MT weekly assessments only one-third of the ses-
sions would have been performed outside the recommended
parameters, while with a single MT assessment almost half are
expected to be performed out of the recommended parameters.
Importantly, one TMSmanufacturer has also supported that weekly
measurements of MT should be performed, and non-compliance of1123such MT assessment schedule has been recognized as a likely
culprit for seizures [43,44].
Our results should nevertheless be interpreted considering the
limitations of the study design. First, this study was mainly sup-
ported by a naturalistic cohort, hence no sham rTMS stimulation
was used. Accordingly, MT variability could be due to natural
neurophysiologic changes, the cumulative effects of rTMS, or other
factors. Additionally, while the absence of a controlled environment
may be considered an important caveat, we believe this can also be
viewed as a strength. Previous evidence for MT stability have been
extracted from highly controlled settings [31]. Such clinical
research environments include highly selected patients’ pop-
ulations, often leading to an important impact on external validity
and generalizability [45]. Hence, a naturalistic study design will
more closely reflect MT variability in the more general patient
population. Second, we have used a retrospective design, relying on
records from a broad time range, where incomplete information is
expected. Nevertheless, analyzing data from a wide range period is
more likely to increase the probability of non-differential infor-
mation/misclassification bias, favoring the null hypothesis instead
of supporting a consistent significant result [46]. However, in order
to address this potential limitation, we have used different strate-
gies to focus on the most accurately reported data, such as
G. Cotovio, A.J. Oliveira-Maia, C. Paul et al. Brain Stimulation 14 (2021) 1118e1125excluding patients who had no information about the first rTMS
session, had changed device during the treatment course, had less
10 rTMS sessions or had infrequent MT assessments. Additionally,
we have performed a number of sensitivity analyses, which
included further analysis of data from a sub-population where
additional information, namely identity of TMS technician, was
available, as well as collecting a prospective sample to assess the
reliability of the procedures that were used to determine MT in the
retrospective cohort. We used MT as defined by visual observation,
which while accepted and broadly used in clinical practice
[28,38,47e51], may be less accurate that EMG-based de-
terminations and thus may introduce greater variability. Finally,
potentially important confounders for MT variability were not
systematically collected, hence not considered, such as medication,
smoking status, coffee and alcohol consumption, sleep duration,
psychiatric and non-psychiatric co-morbidities, among others.
While we believe this should be definitely considered in future
prospective studies, their impact on MT variability is already
known [16e18,20]. In fact, the impact of these potential con-
founders actually supports our conclusions, stressing the impor-
tance of measuring MT more often, especially in the presence of
these MT variability moderators. Thus, we believe that our results,
while speculative and limited by our study design and their asso-
ciated constraints, generate important questions regarding both
safety and efficacy of treatment based on the frequency of MT
measurements. Such data may inform future studies comparing
patients, or TMS Clinical programs, with different MT assessment
scheduling strategies, in prospective designs.5. Conclusion
In conclusion, we found that MT varies significantly on a daily
basis within patients receiving rTMS treatment for depression. This
variability may raise concerns about safety and efficacy of treat-
ment when MT is only measured once at the start of therapy. The
effect of MT variability could be explored in future studies designed
to evaluate the impact of different MT assessment schedules in
these clinical outcomes, though it would be challenging and
naturalistic assessments like those presented here can help inform
the field. These findings highlight the need for revisiting current
rTMS protocols [31], exploring the implementation of more
frequent MT assessments, such that stimulation is delivered
consistently within the recommended intensity. Since it is unlikely
that randomized-control-trials will be performed to demonstrate
the effects of different MT determination frequencies on efficacy
and side-effects, we believe that the evidence presented here
support that more regular, daily or at least weekly, MT determi-
nation in clinical rTMS programs may be considered, to avoid
moderate-to-severe under or overstimulation across a course of
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